---
title: "JCR Pharmaceuticals Announces Correction to Financial Results Material"
date: "2025-02-12 18:22:14"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioThe latest update is out from..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_2170812299-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

The latest update is out from JCR Pharmaceuticals Co., Ltd. ( [(JP:4552)](https://www.tipranks.com/stocks/jp:4552) ).

JCR Pharmaceuticals Co., Ltd. announced a correction to their previously released FY2024 Third Quarter Consolidated Financial Results Conference Call Material. While the specific corrections are not detailed, such amendments are crucial for maintaining transparency and accuracy in financial communications, which could impact stakeholder trust and the company’s market positioning.

**More about JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on delivering therapies for rare and genetic diseases. With a 49-year legacy in Japan, it has expanded its presence globally, including in the US, Europe, and Latin America. The company offers approved therapies for various conditions like growth disorder and Fabry disease and is developing treatments for rare diseases such as MPS I, II, and III.

**YTD Price Performance:** -10.54%

**Average Trading Volume:** 404,149

**Technical Sentiment Consensus Rating:** Strong Buy

**Current Market Cap:** Yen67.2B

For an in-depth examination of 4552 stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/jp:4552/stock-analysis).

Trending Articles:
------------------

* [Here’s One Reason to Hold GameStop Stock, Says Top Investor](https://www.tipranks.com/news/heres-one-reason-to-hold-gamestop-stock-says-top-investor)
* [Baidu to Launch Advanced Generative AI Model Ernie 5 to Rival DeepSeek](https://www.tipranks.com/news/baidu-to-launch-advanced-generative-ai-model-ernie-5-to-rival-deepseek)
* [Cathie Wood’s ARK Makes Big Trades. Sells PLTR and Hood but Buys SHOP, AMD, TSM, and AMZN](https://www.tipranks.com/news/cathie-woods-ark-makes-big-trades-sells-pltr-and-hood-but-buys-shop-amd-tsm-and-amzn)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/jcr-pharmaceuticals-announces-correction-to-financial-results-material)
